Next Generation Orphan Drug Incentives

4:30 PM - 5:25 PM, Monday, June 8, 2020 ・ Track Pacific
Search General Info
Search Education
Search Partnering Companies
The promise of gene and cell therapies, advances in genetic screening and related diagnostics, and precision medicine has generated widespread enthusiasm throughout the rare disease community. At the same time, new patient-focused drug development is giving patient groups a pathway to new treatments. Yet, despite advances, 95% of rare diseases still do not have a treatment.

With Congress considering ways to update the 21st Century Cures Act and new studies imagining future scenarios, this session will explore new approaches to incentives and patient collaboration to foster a new era in orphan drug development for the 30 million Americans suffering with a rare disease.
Sponsored By
Executive Director
Genetic Alliance
Chief Financial Officer
President & CEO
bluebird bio
Founder & Director
IGA Nephropathy Foundation of America
Chair, FDA Regulatory Practice
Lowenstein Sandler Pc